Barasertib-HQPA (AZD2811)

N. catalogoS1147 Lotto:S114707

Stampa

Dati tecnici

Formula

C26H30FN7O3
Peso molecolare 507.56 Numero CAS 722544-51-6
Solubilità (25°C)* In vitro DMSO 100 mg/mL (197.02 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Aggiungere i solventi al prodotto singolarmente e in ordine.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml significa leggermente solubile o insolubile.
* Si prega di notare che Selleck testa la solubilità di tutti i composti internamente e la solubilità effettiva può differire leggermente dai valori pubblicati. Ciò è normale ed è dovuto a leggere variazioni da lotto a lotto.
* Spedizione a temperatura ambiente (I test di stabilità mostrano che questo prodotto può essere spedito senza alcuna misura di raffreddamento.)

Preparazione delle soluzioni stock

Attività biologica

Descrizione Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) è un inibitore altamente selettivo di Aurora B con IC50 di 0,37 nM in un saggio senza cellule, ~3700 volte più selettivo per Aurora B rispetto ad Aurora A. Fase 1.
Target
Aurora B
(Cell-free assay)
0.37 nM
In vitro

Barasertib (AZD1152-HQPA), un inibitore altamente selettivo di Aurora B, causa poliploidia e apoptosi in molte linee cellulari tumorali.
In vivo

Barasertib (AZD1152-HQPA) è un inibitore della chinasi aurora B e ha efficacia contro gli xenotrapianti di linee cellulari di SCLC/RB1, i PDX di SCLC/RB1 e i tumori neuroendocrini/Rb1 autoctoni.

Protocollo (da riferimento)

Saggio cellulare:

[1]
  • Linee cellulari

    NCI-H82 cells, SCLC and NSCLC cell lines

  • Concentrazioni

    --

  • Tempo di incubazione

    --

  • Metodo

    --

Riferimenti

  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368871/
  • https://pubmed.ncbi.nlm.nih.gov/17495131/

Convalida del prodotto da parte del cliente

Targeting PI3K, a common downstream effector of RTKs, with a selective inhibitor (GDC0941) sensitizes SOX10 knockdown cells to vemurafenib. shRNAs targeting SOX10 were introduced into A375 cells by lentiviral transduction. pLKO.1 empty vector served as a control vector (Ctrl). Cells were seeded in 6-well plates at the same density in the presence or absence of drug(s) at the indicated concentration. Cells were cultured for 2 weeks in the absence of vemurafenib or 4 weeks in the presence of vemurafenib before fixing and staining.

Dati da [ Nature , 2014 , 508(7494), 118-22 ]

Primary MKPs were treated with the Aurora B inhibitor AZD-1152, and then stimulated with 20 ng/ml TPO for 5 d. Cell morphology was analyzed by Giemsa staining (Bar, 20 祄; red arrows denote mature MKs; n = 6).

Dati da [ J Exp Med , 2014 , 10.1084/jem.20141123 ]

<p>: Barasertib inhibits AURKB specifically and triggers mitotic slippage. (a) Barasertib inhibits AURKB without affecting AURKA. Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Barasertib for 2 h. Nocodazole and MG132 were included to prevent mitotic exit. Lysates were prepared and analyzed with immunoblotting. Uniform loading was confirmed by immunoblotting for actin. (b) Barasertib induces mitotic slippage. HeLa cells expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Barasertib. Individual cells were then tracked for 24 h with time- lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). The key is the same as in Figure 1b. (c) Summary of Barasertib-mediated mitotic slippage. Live-cell imaging after Barasertib treatment was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period were quantified. (d) Genome reduplication after Barasertib-mediated mitotic slippage. HeLa cells were treated with the indicated concentrations of Barasertib for 36 h. DNA contents were analyzed with flow cytometry. (e) Barasertib induces mitotic slippage and genome reduplication in HCT116. Cells were treated with the indicated concentrations of Barasertib for 24 h. DNA contents were analyzed with flow cytometry. (f) Cytotoxicity induced by Barasertib. HeLa and HCT116 cells were cultured in the presence of the indicated concentrations of Barasertib for 48 h. Proliferation was assayed with WST-1 assay. (g) Barasertib induces genome reduplication and apoptosis. HeLa cells were incubated with 50 n M of Barasertib either in the presence or absence of the caspase inhibitor Z-VAD(OMe)-FMK. The cells were harvested at the indicated time points and analyzed with flow cytometry.</p>

Dati da [ Oncogene , 2014 , 33, 3550-60 ]

<p> </p><p>Dual inhibition of Aurora and SRC kinases specifically eliminates hyperploid cells. Experiment shown is same as a, b, but performed following treatment of OVCAR10 cells with MLN8237 (targeting AURKA) or AZD1152 (targeting AURKB);</p>

Dati da [ Oncogene , 2012 , 31, 1217–1227 ]

Sellecks Barasertib-HQPA (AZD2811) È stato citato da 171 Pubblicazioni

High-throughput screening identifies Aurora kinase B as a critical therapeutic target for Merkel cell carcinoma [ Nat Commun, 2025, 16(1):1583] PubMed: 39939315
Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies [ Cell Rep Med, 2025, 6(2):101964] PubMed: 39933527
Aurora B controls microtubule stability to regulate abscission dynamics in stem cells [ Cell Rep, 2025, 44(2):115238] PubMed: 39854207
Identification of chemical inhibitors targeting long noncoding RNA through gene signature-based high throughput screening [ Int J Biol Macromol, 2025, 292:139119] PubMed: 39722392
Oversized cells activate global proteasome-mediated protein degradation to maintain cell size homeostasis [ Elife, 2025, 14e75393] PubMed: 39791360
The mechanoresponsive chromosomal passenger complex sustains furrow ingression under confinement [ J Mol Cell Biol, 2025, mjaf019] PubMed: 40693957
Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition [ Biochim Biophys Acta Mol Cell Res, 2025, 1872(7):120001] PubMed: 40499687
Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer [ Sci Rep, 2025, 15(1):3211] PubMed: 39863788
Nucleosome stability safeguards cell identity, stress resilience and healthy aging [ bioRxiv, 2025, 2025.09.17.676776] PubMed: 41000743
Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies [ Cell, 2024, 187(1):184-203.e28] PubMed: 38181741

POLITICA DI RESO
La politica di reso incondizionato di Selleck Chemical garantisce ai nostri clienti unesperienza di acquisto online senza problemi. Se non sei in alcun modo soddisfatto del tuo acquisto, puoi restituire qualsiasi articolo entro 7 giorni dalla ricezione. In caso di problemi di qualità del prodotto, sia relativi al protocollo che al prodotto, puoi restituire qualsiasi articolo entro 365 giorni dalla data di acquisto originale. Si prega di seguire le istruzioni seguenti per la restituzione dei prodotti.

SPEDIZIONE E CONSERVAZIONE
I prodotti Selleck vengono trasportati a temperatura ambiente. Se ricevi il prodotto a temperatura ambiente, ti assicuriamo che il Dipartimento di Ispezione Qualità di Selleck ha condotto esperimenti per verificare che la conservazione a temperatura normale per un mese non influirà sullattività biologica dei prodotti in polvere. Dopo la raccolta, conservare il prodotto secondo le indicazioni descritte nella scheda tecnica. La maggior parte dei prodotti Selleck è stabile nelle condizioni raccomandate.

NON PER USO UMANO, DIAGNOSTICO VETERINARIO O TERAPEUTICO.